Author Question: The typical plasma arc cutting torch contains a _____. a. deflector, retaining cup, extended ... (Read 196 times)

karen

  • Hero Member
  • *****
  • Posts: 537
The typical plasma arc cutting torch contains a _____.
 
  a. deflector, retaining cup, extended nozzle, and extended electrode
  b. gouge shield, retaining cup, gouging nozzle, and standard bronze electrode
  c. deflector, gouge shield, retaining cup, and copper electrode
  d. retaining cup, copper electrode with a hafnium or thoriated tungsten insert, gas swirl ring, and nozzle

Question 2

Which of the following safety statements related to plasma arc cutting is true?
 
  a. A hot-work permit is not required for plasma arc cutting due to the nature of the process.
  b. Both methane and propane are lighter than air and rise quickly from the work area if released.
  c. Never carry matches or gas-filled lighters in your pockets.
  d. Unlike oxyfuel cutting, a vessel can be cut safely with plasma regardless of its contents.



chem1s3

  • Sr. Member
  • ****
  • Posts: 320
Answer to Question 1

d

Answer to Question 2

c



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question


 

Did you know?

When taking monoamine oxidase inhibitors, people should avoid a variety of foods, which include alcoholic beverages, bean curd, broad (fava) bean pods, cheese, fish, ginseng, protein extracts, meat, sauerkraut, shrimp paste, soups, and yeast.

Did you know?

When blood is deoxygenated and flowing back to the heart through the veins, it is dark reddish-blue in color. Blood in the arteries that is oxygenated and flowing out to the body is bright red. Whereas arterial blood comes out in spurts, venous blood flows.

Did you know?

The longest a person has survived after a heart transplant is 24 years.

Did you know?

The most common childhood diseases include croup, chickenpox, ear infections, flu, pneumonia, ringworm, respiratory syncytial virus, scabies, head lice, and asthma.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library